CN105980388B - 化合物 - Google Patents
化合物 Download PDFInfo
- Publication number
- CN105980388B CN105980388B CN201580006294.1A CN201580006294A CN105980388B CN 105980388 B CN105980388 B CN 105980388B CN 201580006294 A CN201580006294 A CN 201580006294A CN 105980388 B CN105980388 B CN 105980388B
- Authority
- CN
- China
- Prior art keywords
- pyrrolo
- amino
- pyrimidine
- base
- ketone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 *C(c1c(*)c(N)c(*)c(N)c1*)=O Chemical compound *C(c1c(*)c(N)c(*)c(N)c1*)=O 0.000 description 9
- ZEPTYHJPASGMFX-UHFFFAOYSA-N CCC(C)COC1NC(C)=Nc2c1cc[nH]2 Chemical compound CCC(C)COC1NC(C)=Nc2c1cc[nH]2 ZEPTYHJPASGMFX-UHFFFAOYSA-N 0.000 description 1
- YAHRDLICUYEDAU-RNFRBKRXSA-N CC[C@@H](C)C[C@@H](C)N Chemical compound CC[C@@H](C)C[C@@H](C)N YAHRDLICUYEDAU-RNFRBKRXSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2014000140 | 2014-01-29 | ||
| CNPCT/CN2014/000140 | 2014-01-29 | ||
| PCT/CN2015/000054 WO2015113451A1 (en) | 2014-01-29 | 2015-01-28 | Compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105980388A CN105980388A (zh) | 2016-09-28 |
| CN105980388B true CN105980388B (zh) | 2018-01-16 |
Family
ID=53756223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201580006294.1A Expired - Fee Related CN105980388B (zh) | 2014-01-29 | 2015-01-28 | 化合物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9815841B2 (https=) |
| EP (1) | EP3099694B1 (https=) |
| JP (1) | JP6474826B2 (https=) |
| CN (1) | CN105980388B (https=) |
| AU (2) | AU2015210554A1 (https=) |
| CA (1) | CA2937430A1 (https=) |
| ES (1) | ES2717757T3 (https=) |
| RU (1) | RU2016134751A (https=) |
| WO (1) | WO2015113451A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA39219B1 (fr) | 2014-01-29 | 2018-11-30 | Glaxosmithkline Ip Dev Ltd | Nouveaux composés inhibiteurs de la kinase lrrk2 utilisés pour le traitement du parkinson, de l’alzheimer et de la sclérose latérale amyotrophique |
| CN107801397B (zh) * | 2015-02-13 | 2021-07-30 | 达纳－法伯癌症研究所公司 | Lrrk2抑制剂及其制备和使用方法 |
| JP2018537502A (ja) | 2015-12-16 | 2018-12-20 | サウザーン リサーチ インスチチュート | ピロロピリミジン化合物、キナーゼｌｒｒｋ２阻害剤としての使用、及びその調製方法 |
| WO2018137618A1 (en) * | 2017-01-25 | 2018-08-02 | Glaxosmithkline Intellectual Property Development Limited | Compounds for inhibiting lrrk2 kinase activity |
| BR112019015252A2 (pt) * | 2017-01-25 | 2020-04-14 | Glaxosmithkline Ip Dev Ltd | compostos |
| EP3587422A4 (en) * | 2017-02-22 | 2020-05-06 | Daegu-Gyeongbuk Medical Innovation Foundation | PYRROLOPYRIMIDINE DERIVATIVE COMPOUND, PRODUCTION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION WITH THIS COMPOUND AS AN ACTIVE SUBSTANCE FOR PREVENTING OR TREATING PROTEIN KINASE-RELATED DISEASE |
| CN110662745B (zh) * | 2017-03-23 | 2021-08-03 | 大邱庆北尖端医疗产业振兴财团 | 吡咯并吡啶衍生物、其制备方法、和用于预防或治疗蛋白激酶相关疾病的药物组合物 |
| EP3915985A4 (en) | 2019-01-18 | 2022-09-28 | Voronoi Co., Ltd. | PYRROLOPYRIDE DERIVATIVE AND USE THEREOF FOR THE PREVENTION AND TREATMENT OF PROTEIN KINASE RELATED DISEASES |
| AU2020209789A1 (en) * | 2019-01-18 | 2021-09-16 | Voronoi Co., Ltd. | Pyrrolopyrimidine derivative, and pharmaceutical composition for preventing or treating protein kinase-related disease comprising same as active ingredient |
| CZ308800B6 (cs) | 2019-02-12 | 2021-05-26 | Univerzita Palackého v Olomouci | Heterocyklické dusíkaté deriváty purinu, farmaceutické přípravky obsahující tyto deriváty a jejich použití při neuroprotekci |
| WO2020232332A1 (en) | 2019-05-16 | 2020-11-19 | Dana-Farber Cancer Institute, Inc. | Pyrrolopyrimidine inhibitors of wild-type and mutant forms of lrrk2 |
| CN111205216B (zh) * | 2020-03-11 | 2022-03-29 | 连云港恒运药业有限公司 | 一种制备沙格列汀的方法 |
| EP4238975A4 (en) * | 2020-10-29 | 2024-06-12 | Suzhou Yabao Pharmaceutical R&D Co., Ltd. | SUBSTITUTED DIARYLAMINE COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, MANUFACTURING PROCESS THEREOF AND USE THEREOF |
| KR20220081631A (ko) | 2020-12-09 | 2022-06-16 | 보로노이 주식회사 | 염증성 질환의 예방 및/또는 치료를 위한 피롤로-피리딘 유도체 화합물의 신규 용도 |
| WO2022155419A1 (en) * | 2021-01-15 | 2022-07-21 | ESCAPE Bio, Inc. | Indazoles and azaindazoles as lrrk2 inhibitors |
| JP2024512024A (ja) * | 2021-03-23 | 2024-03-18 | ハリア・セラピューティクス・インコーポレイテッド | Ｌｒｒｋ２キナーゼ阻害剤として有用なピリミジン誘導体 |
| JP2024541934A (ja) | 2021-10-27 | 2024-11-13 | ハー・ルンドベック・アクチエゼルスカベット | Ｌｒｒｋ２阻害剤 |
| CN115108991B (zh) * | 2022-06-30 | 2023-05-05 | 南京理工大学 | 一种硝仿基吡唑起爆药及其制备方法 |
| TW202412777A (zh) | 2022-09-15 | 2024-04-01 | 丹麥商Ｈ 朗德貝克公司 | 富白胺酸重複激酶2（lrrk2）抑制劑 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2537916A1 (en) | 2003-09-03 | 2005-03-31 | Neurogen Corporation | 5-aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds |
| GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| WO2006050076A1 (en) | 2004-10-29 | 2006-05-11 | Janssen Pharmaceutica, N.V. | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders |
| JP2009511528A (ja) * | 2005-10-13 | 2009-03-19 | グラクソ グループ リミテッド | Ｓｙｋ阻害物質としてのピロロピリミジン誘導体群 |
| CA2651072A1 (en) | 2006-05-01 | 2007-11-08 | Pfizer Products Inc. | Substituted 2-amino-fused heterocyclic compounds |
| WO2009036066A1 (en) | 2007-09-10 | 2009-03-19 | Curis, Inc. | Vegfr inhibitors containing a zinc binding moiety |
| US9315449B2 (en) | 2008-05-15 | 2016-04-19 | Duke University | Substituted pyrazoles as heat shock transcription factor activators |
| WO2009143018A2 (en) | 2008-05-19 | 2009-11-26 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
| WO2009143404A1 (en) | 2008-05-23 | 2009-11-26 | Wyeth | Piperazine metabotropic glutamate receptor 5 (mglur5) negative allosteric modulators for anxiety/depression |
| US9908884B2 (en) | 2009-05-05 | 2018-03-06 | Dana-Farber Cancer Institute, Inc. | EGFR inhibitors and methods of treating disorders |
| JP5752691B2 (ja) | 2009-09-29 | 2015-07-22 | グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ | 新規化合物 |
| ES2577829T3 (es) * | 2010-06-04 | 2016-07-19 | F. Hoffmann-La Roche Ag | Derivados de aminopirimidina como moduladores de la LRRK2 |
| WO2011153553A2 (en) | 2010-06-04 | 2011-12-08 | The Regents Of The University Of California | Methods and compositions for kinase inhibition |
| WO2012009258A2 (en) | 2010-07-13 | 2012-01-19 | Edward Roberts | Peptidomimetic galanin receptor modulators |
| WO2012045195A1 (en) | 2010-10-09 | 2012-04-12 | Abbott Laboratories | Pyrrolopyrimidines as fak and alk inhibiters for treatment of cancers and other diseases |
| NO2638031T3 (https=) | 2010-11-10 | 2018-03-10 | ||
| JP2013545749A (ja) | 2010-11-10 | 2013-12-26 | インフィニティー ファーマシューティカルズ， インコーポレイテッド | 複素環化合物及びその使用 |
| WO2012080729A2 (en) | 2010-12-14 | 2012-06-21 | Electrophoretics Limited | CASEIN KINASE 1δ (CK1δ) INHIBITORS |
| AP2013007253A0 (en) * | 2011-04-21 | 2013-11-30 | Origenis Gmbh | Pyrazolo [4,3-D] pyrimidines useful as kinase inhibitors |
| EP2758402B9 (en) | 2011-09-22 | 2016-09-14 | Pfizer Inc | Pyrrolopyrimidine and purine derivatives |
| EP2785381B1 (en) | 2011-11-30 | 2016-05-18 | F.Hoffmann-La Roche Ag | Fluorine-18 and carbon-11 labeled radioligands for positron emission tomography (pet) imaging for lrrk2 |
| GB201204985D0 (en) * | 2012-03-21 | 2012-05-02 | Genentech Inc | Compounds |
| EP2844652B1 (en) | 2012-05-03 | 2019-03-13 | Genentech, Inc. | Pyrazole aminopyrimidine derivatives as lrrk2 modulators |
| KR102091895B1 (ko) | 2012-05-03 | 2020-04-14 | 제넨테크, 인크. | 파킨슨병의 치료에 사용하기 위한 lrrk2 조절제로서의 피라졸 아미노피리미딘 유도체 |
| EP2867236B1 (en) * | 2012-06-29 | 2017-06-14 | Pfizer Inc | Novel 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors |
| MA39219B1 (fr) | 2014-01-29 | 2018-11-30 | Glaxosmithkline Ip Dev Ltd | Nouveaux composés inhibiteurs de la kinase lrrk2 utilisés pour le traitement du parkinson, de l’alzheimer et de la sclérose latérale amyotrophique |
-
2015
- 2015-01-28 RU RU2016134751A patent/RU2016134751A/ru not_active Application Discontinuation
- 2015-01-28 AU AU2015210554A patent/AU2015210554A1/en not_active Abandoned
- 2015-01-28 US US15/114,857 patent/US9815841B2/en not_active Expired - Fee Related
- 2015-01-28 WO PCT/CN2015/000054 patent/WO2015113451A1/en not_active Ceased
- 2015-01-28 CN CN201580006294.1A patent/CN105980388B/zh not_active Expired - Fee Related
- 2015-01-28 EP EP15743645.2A patent/EP3099694B1/en active Active
- 2015-01-28 CA CA2937430A patent/CA2937430A1/en not_active Abandoned
- 2015-01-28 ES ES15743645T patent/ES2717757T3/es active Active
- 2015-01-28 JP JP2016549113A patent/JP6474826B2/ja not_active Expired - Fee Related
-
2018
- 2018-01-12 AU AU2018200271A patent/AU2018200271A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2015210554A1 (en) | 2016-07-07 |
| CN105980388A (zh) | 2016-09-28 |
| WO2015113451A1 (en) | 2015-08-06 |
| RU2016134751A (ru) | 2018-03-02 |
| US9815841B2 (en) | 2017-11-14 |
| JP2017504635A (ja) | 2017-02-09 |
| AU2018200271A1 (en) | 2018-02-01 |
| EP3099694A4 (en) | 2017-06-14 |
| EP3099694A1 (en) | 2016-12-07 |
| ES2717757T3 (es) | 2019-06-25 |
| US20170022204A1 (en) | 2017-01-26 |
| EP3099694B1 (en) | 2019-01-16 |
| CA2937430A1 (en) | 2015-08-06 |
| JP6474826B2 (ja) | 2019-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105980388B (zh) | 化合物 | |
| TWI801372B (zh) | 作為a2a抑制劑的硫胺甲酸酯衍生物以及用於癌症治療的方法 | |
| JP6745824B2 (ja) | 複素環化合物 | |
| JP6832342B2 (ja) | 複素環化合物 | |
| KR101792837B1 (ko) | 키나아제 억제제로서 사용을 위한 이미다조피라진 | |
| CN110650959B (zh) | 治疗化合物和组合物及其使用方法 | |
| JP2020526543A (ja) | ロイシンリッチリピートキナーゼ２の阻害剤 | |
| WO2018030466A1 (ja) | 複素環化合物 | |
| CN110678472B (zh) | 作为a2a抑制剂的2-氧代噻唑衍生物和用于治疗癌症的化合物 | |
| JP7228318B6 (ja) | 処置用化合物及び組成物、並びにその使用方法 | |
| WO2018137607A1 (en) | Compounds | |
| CN1842529A (zh) | 用作蛋白激酶抑制剂的化合物和组合物 | |
| KR20160106623A (ko) | 화합물 | |
| CN114008050B (zh) | Jak激酶的吡唑并嘧啶芳基醚抑制剂及其用途 | |
| CN111587250A (zh) | 作为jak抑制剂的吡唑并嘧啶化合物 | |
| CN121487934A (zh) | 能够用于治疗smarca4缺失型癌症的作为smarca2抑制剂的1.6-萘啶化合物 | |
| EP4277893A1 (en) | Indole derivatives as kinase inhibitors | |
| HK40091436A (zh) | 作为a2a抑制剂的2-氧代噻唑衍生物和用於治疗癌症的化合物 | |
| HK40089309A (zh) | 作为a2a抑制剂的2-氧代噻唑衍生物和用於治疗癌症的化合物 | |
| HK40019825A (en) | Therapeutic compounds and compositions, and methods of use thereof | |
| HK40029259A (en) | Pyrazolopyrimidine compounds as jak inhibitors | |
| HK40019824B (en) | Therapeutic compounds and compositions, and methods of use thereof | |
| HK40019824A (en) | Therapeutic compounds and compositions, and methods of use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20180116 Termination date: 20190128 |